References
Key articles
Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord. 2017 Jun;32(6):853-64.Full text Abstract
Bluett B, Pantelyat AY, Litvan I, et al. Best practices in the clinical management of progressive supranuclear palsy and corticobasal syndrome: a consensus statement of the CurePSP Centers of Care. Front Neurol. 2021 Jul 1;12:694872.Full text Abstract
Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996 Jul;47(1):1-9. Abstract
Reference articles
1. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964 Apr;10:333-59. Abstract
2. Olfati N, Shoeibi A, Litvan I. Clinical spectrum of tauopathies. Front Neurol. 2022 Jul 14;13:944806.Full text Abstract
3. Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord. 2017 Jun;32(6):853-64.Full text Abstract
4. Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014 Dec;29(14):1758-66. Abstract
5. Nath U, Ben-Shlomo Y, Thomson RG, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain. 2001 Jul;124(pt 7):1438-49.Full text Abstract
6. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999 Nov 20;354(9192):1771-5. Abstract
7. Takigawa H, Kitayama M, Wada-Isoe K, et al. Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade. Brain Behav. 2016 Dec;6(12):e00557.Full text Abstract
8. Swallow DMA, Zheng CS, Counsell CE. Systematic review of prevalence studies of progressive supranuclear palsy and corticobasal syndrome. Mov Disord Clin Pract. 2022 Jul;9(5):604-13.Full text Abstract
9. Savica R, Grossardt BR, Bower JH, et al. Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol. 2013 Jul;70(7):859-66.Full text Abstract
10. Bluett B, Pantelyat AY, Litvan I, et al. Best practices in the clinical management of progressive supranuclear palsy and corticobasal syndrome: a consensus statement of the CurePSP Centers of Care. Front Neurol. 2021 Jul 1;12:694872.Full text Abstract
11. Bessemer R, Iansavichene A, Jenkins ME, et al. Clinical milestones as triggers for palliative care intervention in progressive supranuclear palsy and multiple system atrophy. J Neurol Sci. 2023 May 15;448:120614. Abstract
12. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain. 2005 Jun;128(Pt 6):1247-58.Full text Abstract
13. Morgan JC, Ye X, Mellor JA, et al. Disease course and treatment patterns in progressive supranuclear palsy: a real-world study. J Neurol Sci. 2021 Feb 15;421:117293. Abstract
14. Boxer AL, Yu JT, Golbe LI, et al. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 2017 Jul;16(7):552-63.Full text Abstract
15. Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999 Apr;8(4):711-5.Full text Abstract
16. Höglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011 Jun 19;43(7):699-705.Full text Abstract
17. Litvan I, Proudfoot JA, Martin ER, et al. Gene-environment interactions in progressive supranuclear palsy. Front Neurol. 2021 Apr 9;12:664796.Full text Abstract
18. Chen JA, Chen Z, Won H, et al. Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. Mol Neurodegener. 2018 Aug 8;13(1):41.Full text Abstract
19. Sanchez-Contreras MY, Kouri N, Cook CN, et al. Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Mol Neurodegener. 2018 Jul 9;13(1):37.Full text Abstract
20. Caparros-Lefebvre D, Golbe LI, Deramecourt V, et al. A geographical cluster of progressive supranuclear palsy in northern France. Neurology. 2015 Oct 13;85(15):1293-300.Full text Abstract
21. Litvan I, Lees PS, Cunningham CR, et al. Environmental and occupational risk factors for progressive supranuclear palsy: case-control study. Mov Disord. 2016 May;31(5):644-52.Full text Abstract
22. Kelley KD, Peavy G, Edland S, et al. The role of stress as a risk factor for progressive supranuclear palsy. J Parkinsons Dis. 2017;7(2):377-83.Full text Abstract
23. Kelley KD, Checkoway H, Hall DA, et al. Traumatic brain injury and firearm use and risk of progressive supranuclear palsy among veterans. Front Neurol. 2018 Jun 20;9:474.Full text Abstract
24. Park HK, Ilango S, Charriez CM, et al. Lifetime exposure to estrogen and progressive supranuclear palsy: environmental and genetic PSP study. Mov Disord. 2018 Mar;33(3):468-72.Full text Abstract
25. Shoeibi A, Olfati N, Litvan I. Frontrunner in translation: progressive supranuclear palsy. Front Neurol. 2019 Oct 22;10:1125.Full text Abstract
26. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994 Nov;44(11):2015-9. Abstract
27. Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020 Aug;140(2):99-119.Full text Abstract
28. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996 Jul;47(1):1-9. Abstract
29. Viscidi E, Litvan I, Dam T, et al. Clinical features of patients with progressive supranuclear palsy in an US insurance claims database. Front Neurol. 2021 Jun 17;12:571800.Full text Abstract
30. McFarland NR, Hess CW. Recognizing atypical parkinsonisms: "red flags" and therapeutic approaches. Semin Neurol. 2017 Apr;37(2):215-27.Full text Abstract
31. Bhidayasiri R, Sringean J, Reich SG, et al. Red flags phenotyping: a systematic review on clinical features in atypical parkinsonian disorders. Parkinsonism Relat Disord. 2019 Feb;59:82-92. Abstract
32. Williams DR, Litvan I. Parkinsonian syndromes. Continuum (Minneap Minn). 2013 Oct;19(5):1189-212.Full text Abstract
33. Brown FS, Rowe JB, Passamonti L, et al. Falls in progressive supranuclear palsy. Mov Disord Clin Pract. 2020 Jan;7(1):16-24.Full text Abstract
34. European Reference Network for Rare Neurological Diseases (ERN-RND). Brief and focused information on the diagnosis of atypical parkinsonism for general neurologists/general practitioners. Jun 2020 [internet publication].Full text
35. Golbe LI, Ohman-Strickland P, Beisser EB, et al. A convenient prognostic tool and staging system for progressive supranuclear palsy. Mov Disord Clin Pract. 2020 Aug;7(6):664-71.Full text Abstract
36. Goetz CG, Leurgans S, Lang AE, et al. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology. 2003 Mar 25;60(6):917-22. Abstract
37. Gerstenecker A, Mast B, Duff K, et al. Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy. Arch Clin Neuropsychol. 2013 Mar;28(2):104-13.Full text Abstract
38. Pilotto A, Gazzina S, Benussi A, et al. Mild cognitive impairment and progression to dementia in progressive supranuclear palsy. Neurodegener Dis. 2017;17(6):286-91. Abstract
39. Gerstenecker A, Duff K, Mast B, et al. Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Res. 2013 Dec 30;210(3):1205-10.Full text Abstract
40. Litvan I, Mega MS, Cummings JL, et al. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology. 1996 Nov;47(5):1184-9. Abstract
41. Flavell J, Nestor PJ. A systematic review of apathy and depression in progressive supranuclear palsy. J Geriatr Psychiatry Neurol. 2022 May;35(3):280-92. Abstract
42. Rowe JB, Holland N, Rittman T. Progressive supranuclear palsy: diagnosis and management. Pract Neurol. 2021 Oct;21(5):376-83.Full text Abstract
43. Reimann M, Schmidt C, Herting B, et al. Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. J Neural Transm (Vienna). 2010 Jan;117(1):69-76. Abstract
44. Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord. 2010 Feb 15;25(3):357-62. Abstract
45. Han HJ, Kim H, Park JH, et al. Behavioral changes as the earliest clinical manifestation of progressive supranuclear palsy. J Clin Neurol. 2010 Sep;6(3):148-51.Full text Abstract
46. Hassan A, Parisi JE, Josephs KA. Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia. Neurocase. 2012;18(6):478-88. Abstract
47. Josephs KA, Boeve BF, Duffy JR, et al. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase. 2005 Aug;11(4):283-96. Abstract
48. Josephs KA, Duffy JR. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Curr Opin Neurol. 2008 Dec;21(6):688-92. Abstract
49. Santos-Santos MA, Mandelli ML, Binney RJ, et al. Features of patients with nonfluent/agrammatic primary progressive aphasia with underlying progressive supranuclear palsy pathology or corticobasal degeneration. JAMA Neurol. 2016 Jun 1;73(6):733-42.Full text Abstract
50. Ling H, de Silva R, Massey LA, et al. Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant. Neuropathol Appl Neurobiol. 2014 Feb;40(2):149-63.Full text Abstract
51. Müller J, Seppi K, Stefanova N, et al. Freezing of gait in postmortem-confirmed atypical parkinsonism. Mov Disord. 2002 Sep;17(5):1041-5. Abstract
52. Rezvanian S, Litvan I, Standaert D, et al. Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. Parkinsonism Relat Disord. 2020 Sep;78:56-60. Abstract
53. Facheris MF, Maniak S, Scaravilli F, et al. Pure akinesia as initial presentation of PSP: a clinicopathological study. Parkinsonism Relat Disord. 2008 Aug;14(6):517-9. Abstract
54. Compta Y, Valldeoriola F, Tolosa E, et al. Long lasting pure freezing of gait preceding progressive supranuclear palsy: a clinicopathological study. Mov Disord. 2007 Oct 15;22(13):1954-8. Abstract
55. Amano S, Skinner JW, Lee HK, et al. Discriminating features of gait performance in progressive supranuclear palsy. Parkinsonism Relat Disord. 2015 Aug;21(8):888-93. Abstract
56. Otero-Millan J, Schneider R, Leigh RJ, et al. Saccades during attempted fixation in parkinsonian disorders and recessive ataxia: from microsaccades to square-wave jerks. PLoS One. 2013;8(3):e58535.Full text Abstract
57. Shaffer DM, Krisky CM, Sweeney JA. Frequency and metrics of square-wave jerks: influences of task-demand characteristics. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1082-7.Full text Abstract
58. Burrell JR, Hodges JR, Rowe JB. Cognition in corticobasal syndrome and progressive supranuclear palsy: a review. Mov Disord. 2014 Apr 15;29(5):684-93. Abstract
59. Fiorenzato E, Weis L, Falup-Pecurariu C, et al. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. J Neural Transm (Vienna). 2016 Dec;123(12):1435-42. Abstract
60. Peterson KA, Patterson K, Rowe JB. Language impairment in progressive supranuclear palsy and corticobasal syndrome. J Neurol. 2021 Mar;268(3):796-809.Full text Abstract
61. Rusz J, Bonnet C, Klempíř J, et al. Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. J Neurol. 2015;262(4):992-1001. Abstract
62. Clark HM, Utianski RL, Ali F, et al. Motor speech disorders and communication limitations in progressive supranuclear palsy. Am J Speech Lang Pathol. 2021 Jun 18;30(3s):1361-72.Full text Abstract
63. Verny M, Jellinger KA, Hauw JJ, et al. Progressive supranuclear palsy: a clinicopathological study of 21 cases. Acta Neuropathol. 1996;91(4):427-31. Abstract
64. Barclay CL, Lang AE. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1997 Apr;62(4):352-6.Full text Abstract
65. Golbe LI, Davis PH, Lepore FE. Eyelid movement abnormalities in progressive supranuclear palsy. Mov Disord. 1989;4(4):297-302. Abstract
66. Leiguarda RC, Pramstaller PP, Merello M, et al. Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. Brain. 1997 Jan;120 (Pt 1):75-90.Full text Abstract
67. Soliveri P, Piacentini S, Girotti F. Limb apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology. 2005 Feb 8;64(3):448-53. Abstract
68. Stejskalova Z, Rohan Z, Rusina R, et al. Pyramidal system involvement in progressive supranuclear palsy: a clinicopathological correlation. BMC Neurol. 2019 Mar 20;19(1):42.Full text Abstract
69. American College of Radiology. ACR appropriateness criteria: movement disorders and neurodegenerative diseases. 2019 [internet publication].Full text
70. Albrecht F, Bisenius S, Neumann J, et al. Atrophy in midbrain and cerebral/cerebellar pedunculi is characteristic for progressive supranuclear palsy: a double-validation whole-brain meta-analysis. Neuroimage Clin. 2019;22:101722.Full text Abstract
71. Nigro S, Morelli M, Arabia G, et al. Magnetic Resonance Parkinsonism Index and midbrain to pons ratio: which index better distinguishes progressive supranuclear palsy patients with a low degree of diagnostic certainty from patients with Parkinson disease? Parkinsonism Relat Disord. 2017 Aug;41:31-6. Abstract
72. Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology. 2008 Jan;246(1):214-21. Abstract
73. Kim S, Suh CH, Shim WH, et al. Diagnostic performance of the Magnetic Resonance Parkinsonism Index in differentiating progressive supranuclear palsy from Parkinson’s disease: an updated systematic review and meta-analysis. Diagnostics (Basel). 2021 Dec 22;12(1):12.Full text Abstract
74. Quattrone A, Morelli M, Nigro S, et al. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease. Parkinsonism Relat Disord. 2018 Sep;54:3-8. Abstract
75. Nobili F, Arbizu J, Bouwman F, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain (18) F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018 Oct;25(10):1201-17.Full text Abstract
76. Magherini A, Pentore R, Grandi M, et al. Progressive supranuclear gaze palsy without parkinsonism: a case of neuro-Whipple. Parkinsonism Relat Disord. 2007 Oct;13(7):449-52. Abstract
77. Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology. 2023 Apr 1;77(4):1428-55.Full text Abstract
78. Satoh K, Shirabe S, Eguchi H, et al. 14-3-3 protein, total tau and phosphorylated tau in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease and neurodegenerative disease in Japan. Cell Mol Neurobiol. 2006 Feb;26(1):45-52. Abstract
79. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021 Jun 12;397(10291):2284-303. Abstract
80. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct;30(12):1591-601. Abstract
81. Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023 May;22(5):407-17.Full text Abstract
82. Armstrong RA. Visual signs and symptoms of corticobasal degeneration. Clin Exp Optom. 2016 Nov;99(6):498-506. Abstract
83. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013 Jan 29;80(5):496-503.Full text Abstract
84. Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009 Jan;132(Pt 1):156-71.Full text Abstract
85. Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society criteria for the diagnosis of multiple system atrophy. Mov Disord. 2022 Jun;37(6):1131-48.Full text Abstract
86. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 4;89(1):88-100.Full text Abstract
87. Thijssen EH, La Joie R, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021 Sep;20(9):739-52.Full text Abstract
88. Centers for Disease Control and Prevention. Creutzfeldt-Jakob disease, classic (CJD): diagnostic criteria. 2018 [internet publication].Full text
89. Poujois A, Woimant F. Challenges in the diagnosis of Wilson disease. Ann Transl Med. 2019 Apr;7(suppl 2):S67.Full text Abstract
90. Wu M, Ceponiene R, Bayram E, et al. Two patients with Niemann Pick disease type C diagnosed in the seventh decade of life. Mov Disord Clin Pract. 2020 Nov;7(8):961-4.Full text Abstract
91. Hendriksz CJ, Pineda M, Fahey M, et al. The Niemann-Pick Disease Type C Suspicion Index: development of a new tool to aid diagnosis. J Rare Dis Diagn Ther. 2015;1:1.
92. Gerard A, Sarrot-Reynauld F, Liozon E, et al. Neurologic presentation of Whipple disease: report of 12 cases and review of the literature. Medicine (Baltimore). 2002 Nov;81(6):443-57.Full text Abstract
93. Bluett B, Ash E, Farheen A, et al. Clinical features of idiopathic normal pressure hydrocephalus: critical review of objective findings. Mov Disord Clin Pract. 2023 Jan;10(1):9-16.Full text Abstract
94. Marmarou A, Bergsneider M, Klinge P, et al. The value of supplemental prognostic tests for the preoperative assessment of idiopathic normal-pressure hydrocephalus. Neurosurgery. 2005 Sep;57(3 suppl):S17-28. Abstract
95. Hashimoto M, Ishikawa M, Mori E, et al. Diagnosis of idiopathic normal pressure hydrocephalus is supported by MRI-based scheme: a prospective cohort study. Cerebrospinal Fluid Res. 2010 Oct 31;7:18.Full text Abstract
96. Mahoney CJ, Sleeman R, Errington W. Assessment of suspected motor neuron disease. BMJ. 2022 Nov 23;379:e073857. Abstract
97. Olfati N, Ghodsi H, Bayram E, et al. Why therapeutic trials fail in primary tauopathies. Mov Disord. 2023 Apr;38(4):545-50.Full text Abstract
98. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol. 1993 Aug;16(4):338-46. Abstract
99. Frequin HL, Schouten J, Verschuur CVM, et al. Levodopa response in patients with early Parkinson disease: further observations of the LEAP study. Neurology. 2023 Jan 24;100(4):e367-76. Abstract
100. Stamelou M, Höglinger G. A review of treatment options for progressive supranuclear palsy. CNS Drugs. 2016 Jul;30(7):629-36. Abstract
101. Akbar U, McQueen RB, Bemski J, et al. Prognostic predictors relevant to end-of-life palliative care in Parkinson's disease and related disorders: a systematic review. J Neurol Neurosurg Psychiatry. 2021 Mar 31;92(6):629-36.Full text Abstract
102. Williams DR, Watt HC, Lees AJ. Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):468-73.Full text Abstract
103. Slade SC, Finkelstein DI, McGinley JL, et al. Exercise and physical activity for people with progressive supranuclear palsy: a systematic review. Clin Rehabil. 2020 Jan;34(1):23-33.Full text Abstract
104. Matsuda N, Takamatsu Y, Aiba I. Effect of therapeutic exercise on the balance of patients with progressive supranuclear palsy: a pilot study. Front Neurol. 2022 Sep 13;13:955893.Full text Abstract
105. Pantelyat A, Dayanim G, Kang K, et al. Rhythmic auditory cueing in atypical parkinsonism: a pilot study. Front Neurol. 2022 Oct 28;13:1018206.Full text Abstract
106. Cosentino C, Putzolu M, Mezzarobba S, et al. One cue does not fit all: a systematic review with meta-analysis of the effectiveness of cueing on freezing of gait in Parkinson's disease. Neurosci Biobehav Rev. 2023 Jul;150:105189. Abstract
107. Kondo T. Drug intervention for freezing of gait resistant to dopaminergic therapy: a pilot study. Parkinsonism Relat Disord. 2006;12:S63-6.
108. Dale ML, Brumbach BH, Boxer AL, et al. Associations between amantadine usage, gait, and cognition in PSP: a post-hoc analysis of the davunetide trial. Front Neurol. 2020 Dec 21;11:606925.Full text Abstract
109. Rajrut AH, Uitti RJ, Fenton ME, et al. Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord. 1997 Dec;3(4):211-4. Abstract
110. Müller J, Wenning GK, Verny M, et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol. 2001 Feb;58(2):259-64.Full text Abstract
111. Nath U, Thomson R, Wood R, et al. Population based mortality and quality of death certification in progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). J Neurol Neurosurg Psychiatry. 2005 Apr;76(4):498-502.Full text Abstract
112. Litvan I, Sastry N, Sonies BC. Characterizing swallowing abnormalities in progressive supranuclear palsy. Neurology. 1997 Jun;48(6):1654-62. Abstract
113. Miles A, Jardine M, Johnston F, et al. Effect of Lee Silverman Voice Treatment (LSVT LOUD®) on swallowing and cough in Parkinson's disease: a pilot study. J Neurol Sci. 2017 Dec 15;383:180-7. Abstract
114. El Sharkawi A, Ramig L, Logemann JA, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry. 2002 Jan;72(1):31-6.Full text Abstract
115. Nozaki S, Fujiu-Kurachi M, Tanimura T, et al. Effects of Lee Silverman Voice Treatment (LSVT LOUD) on swallowing in patients with progressive supranuclear palsy: a pilot study. Prog Rehabil Med. 2021 Feb 20;6:20210012.Full text Abstract
116. Arbouw ME, Movig KL, Koopmann M, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology. 2010 Apr 13;74(15):1203-7. Abstract
117. Ruiz-Roca JA, Pons-Fuster E, Lopez-Jornet P. Effectiveness of the botulinum toxin for treating sialorrhea in patients with Parkinson’s disease: a systematic review. J Clin Med. 2019 Mar 6;8(3):317.Full text Abstract
118. Yu YC, Chung CC, Tu YK, et al. Efficacy and safety of botulinum toxin for treating sialorrhea: a systematic review and meta-analysis. Eur J Neurol. 2022 Jan;29(1):69-80.Full text Abstract
119. Isaacson SH, Ondo W, Jackson CE, et al. Safety and efficacy of rimabotulinumtoxinb for treatment of sialorrhea in adults: a randomized clinical trial. JAMA Neurol. 2020 Apr 1;77(4):461-9.Full text Abstract
120. Steenbakkers RJHM, van Doornik SP, Vissink A, et al. Radiation of parotid or submandibular glands is effective for drooling in patients with parkinsonism; a randomised double-blind placebo-controlled trial. Clin Park Relat Disord. 2022 Feb 14;6:100138.Full text Abstract
121. Sale P, Castiglioni D, De Pandis MF, et al. The Lee Silverman Voice Treatment (LSVT®) speech therapy in progressive supranuclear palsy. Eur J Phys Rehabil Med. 2015 Oct;51(5):569-74.Full text Abstract
122. Kim JH, McCann CM. Communication impairments in people with progressive supranuclear palsy: a tutorial. J Commun Disord. 2015 Jul-Aug;56:76-87. Abstract
123. Rittman T, Coyle-Gilchrist IT, Rowe JB. Managing cognition in progressive supranuclear palsy. Neurodegener Dis Manag. 2016 Dec;6(6):499-508.Full text Abstract
124. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004 Oct 26;63(8):1364-70. Abstract
125. Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006 May;59(5):780-7. Abstract
126. Hammond FM, Sauve W, Ledon F, et al. Safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect among study participants with traumatic brain injury: results from the PRISM-II open label study. PM R. 2018 Oct;10(10):993-1003.Full text Abstract
127. Macedo AC, Mariano LI, Martins MI, et al. Do patients with progressive supranuclear palsy have episodic memory impairment? A systematic review. Mov Disord Clin Pract. 2022 May;9(4):436-45.Full text Abstract
128. Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001 Aug 14;57(3):467-73. Abstract
129. Vercelletto M, Boutoleau-Bretonnière C, Volteau C, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis. 2011;23(4):749-59. Abstract
130. Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013 Feb;12(2):149-56.Full text Abstract
131. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2016 May 10;86(19):1818-26.Full text Abstract
132. National Institute for Health and Care Excellence. Suspected neurological conditions: recognition and referral. Oct 2023 [internet publication].Full text
133. Iyer JM, Gunzler D, Lang AE, et al. Concomitant medications for progressive supranuclear palsy: a secondary analysis of a randomized clinical trial. JAMA Neurol. 2024 Mar 1;81(3):295-7. Abstract
134. Coyle-Gilchrist IT, Dick KM, Patterson K, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology. 2016 May 3;86(18):1736-43.Full text Abstract
135. Jecmenica-Lukic M, Petrovic IN, Pekmezovic T, et al. Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study. J Neurol. 2014 Aug;261(8):1575-83. Abstract
136. Ahmed Z, Josephs KA, Gonzalez J, et al. Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy. Brain. 2008 Feb;131(pt 2):460-72.Full text Abstract
137. Glasmacher SA, Leigh PN, Saha RA. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017 May;88(5):402-11. Abstract
Use of this content is subject to our disclaimer